8:40 AM
 | 
Jul 12, 2018
 |  BC Innovations  |  Translation in Brief

Reviving NK cells

How targeting TIGIT unleashes the cancer-fighting activity of NK cells

Researchers from the University of Science and Technology of China have identified a key role for TIGIT in NK cell exhaustion that suggests immunotherapies targeting TIGIT may be useful against cancers that have failed to respond to current checkpoint inhibitors.

T cell immunoreceptors with Ig and ITIM domains (TIGIT) is a co-inhibitory checkpoint receptor and an emerging target for immunotherapies designed to overcome tumor-induced immune suppression of T cells. Blocking TIGIT, especially when combined with other checkpoint inhibitors, reverses cytotoxic T lymphocyte (CTL) exhaustion and impairs tumor growth.

In a Nature Immunology study published last month, a team led by Zhigang Tian has now elucidated a primary role for TIGIT in NK cell exhaustion. The findings add TIGIT to a growing list of NK cell checkpoint inhibitors whose blockade could improve patient responses and reduce toxicity observed for T cell-directed checkpoint therapies (see...

Read the full 705 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$85 USD
More Info >